Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 15/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3330442 | 0.74 | SCN9A (0.35) | SCN9AALDH1A1KMT2AMAPTHSD17B10 | |
| SCHEMBL281938 | 0.73 | SCN9A (0.60) | SCN9A | |
| SCHEMBL3335377 | 0.69 | SCN9A (0.40) | SCN9AALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL3330437 | 0.67 | SCN9A (0.38) | SCN9AALDH1A1MEN1KMT2AUSP2 | |
| SCHEMBL4155878 | 0.66 | LMNA (0.38) | SCN9AALDH1A1KMT2AMAPTLMNA | |
| SCHEMBL3330328 | 0.65 | SCN9A (0.43) | SCN9AALDH1A1MAPTLMNA | |
| SCHEMBL3330821 | 0.65 | SCN9A (0.49) | SCN9AALDH1A1 | |
| SCHEMBL484184 | 0.65 | SCN9A (0.42) | SCN9AALDH1A1 | |
| SCHEMBL2305027 | 0.64 | SCN9A (0.60) | SCN9A | |
| SCHEMBL4732564 | 0.63 | SCN9A (1.00) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | SCN9A 61/4885ALDH1A1 1020/4885MEN1 2591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.